Heart failure & cardiomyopathies
Association between sacubitril/valsartan and risk of dementia in patients with heart failure: a nationwide cohort study
Main finding · Incident dementiaResult — go to the resultHazard ratio 0.84 95% CI 0.72–0.98Authors' conclusion
Despite plausible biological mechanisms, no association between sacubitril/valsartan and an increased risk of dementia was observed in patients with HF.
Study context
- Population
- Patients diagnosed with heart failure (HF) and prescribed either sacubitril/valsartan or angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) within 90 days of their first HF diagnosis between October 2017 and December 2020, South Korea7,085 sacubitril/valsartan users and 359,153 ACEI/ARB users before matching · sacubitril/valsartan users 7,085 · ACEI/ARB users 359,153
- Participants
- 6,930 vs 27,720
- Exposure
- Sacubitril/valsartan compared with ACEI/ARB
- sacubitril/valsartann = 6,930
- ACEI/ARBn = 27,720reference
- Outcome
- Incident dementia
- Follow-up
- Mean 2.2 and 2.3 years
Methodological details1:4 propensity score matching, National Health Insurance Database in South Korea
- 1:4 propensity score matching
- National Health Insurance Database in South Korea
Main finding
Incident dementia
Hazard ratio
0.84
95% CI 0.72–0.98
Events by group
Sacubitril/valsartan vs ACEI/ARB
HR 0.84 (95% CI 0.72–0.98)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Alzheimer's dementia
- Of 1180 cases of incident dementia, categorized as Alzheimer's dementia
- 1079 (91.4%)
- Statistical significance was not reached in this main group
Original publication
Association between sacubitril/valsartan and risk of dementia in patients with heart failure: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. Published 21 May 2025. doi:10.
Summarised from the published abstract; every number is checked against it